We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
France is tightening restrictions on early-phase clinical trials in the wake of one study that left one patient brain-dead and hospitalized five others. Read More
European regulators are proposing a series of indirect methods for driving down prescription drug costs without stepping outside the science-focused parameters of their roles. Read More
Generic trade groups and patient advocacy organizations are taking competing stances in their recommendations for the FDA’s biosimilar labeling draft guidance. Read More
France is tightening restrictions on early-phase clinical trials in the wake of one study that left one patient brain-dead and hospitalized five others. Read More
The Secretary’s Advisory Committee on Human Research Protections is recommending the FDA revise its informed consent waivers for cluster randomized trials to mirror HHS rules. Read More
The European Union wants to expand ongoing trade talks between the U.S. and EU to address regulatory harmonization on drug approval requirements. Read More
The Secretary’s Advisory Committee on Human Research Protections is recommending revisions to the Common Rule that would provide further guidance on single IRB reviews. Read More
The U.S. Government Accountability Office faulted the FDA’s approach to regulatory science and its strategic management plan in two reports the agency issued Wednesday critical of the agency. Read More
A former FDA official has been hit with insider-trading charges by the Securities and Exchange Commission for supposedly sending confidential information about FDA approvals to a hedge fund manager. Read More